Skip to content

A 5-Year Follow-up Study Investigating Factors Associated With Osteoporotic Fracture in Chinese Postmenopausal Women

A 5-Year Long-term Follow-up Study of a Cross-Sectional Cohort Study (PK-VF) For the Examination of the Association of Vitamin D/Bone Turnover/Bone Mineral Density With an Incident Fracture in Chinese Postmenopausal Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02247011
Acronym
PK-VF
Enrollment
1100
Registered
2014-09-23
Start date
2013-03-31
Completion date
2016-05-31
Last updated
2016-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporotic Fractures, Osteoporosis, Postmenopausal

Keywords

bone mineral density, 25(OH)D

Brief summary

This proposed study was designed to investigate the prevalence of a 5-year incident osteoporotic fracture and evaluate the association of a 5-year change of 25-hydroxyvitamin D (25\[OH\]D)/bone turnover makers/bone mineral density (BMD) with the incident fracture in the Chinese postmenopausal women, based on an endeavor of a 5-year post-baseline follow-up visit of a previous cross-sectional study, PK-VF, in which 1724 participants were enrolled and examined.

Detailed description

1. In 2013, 5 years after PK-VF, the same 2070 subjects were contacted by the original sites. Among them 1242 subjects were able to come for the follow-up assessment. 2. Clinical assessments: The participant's bio-information, physical examination and medical history were collected;Questionnaire including social/life style and medical evaluations (years since menopause (YSM), fracture history, milk/yoghourt/coffee/wine intake, calcium intake, or smoking history) were collected by PK-VF investigators. Non-vertebral fracture history evaluation: specific non-vertebral fracture sites include rib or clavicle, forearm, upper arm, hand (including wrist), pelvis, hip, thigh (not including hip), leg, and foot (including ankle). When non-vertebral fractures are suspected, questions were raised to the participant to eliminate possible biases (How did you get these fractures, a slight fall at home, fell from a high place, hit by someone, broken during a car accident or an operation? Did you see a doctor to confirm these fractures?) A fracture occurred in regular daily activities or due to mild trauma was defined as fragile non-vertebral fracture. 3. Biochemical measurements: Fasting blood sample (\ 5 ml) was collected from each participant at participating sites; In 2007-2008 study, blood samples were collected during April-July, while in the 5-year follow-up; samples were collected in the same period of time. C-terminal telopeptide of type I collagen (β-CTX), N-aminoterminal prepeptide of type I procollagen (P1NP), and 25 (OH) D will be determined by a laboratory method of electrochemiluminescence (E170; Roche Diagnostics, Basel, Switzerland) in the institute (Peking Union); Chemistry including alkaline phosphatase (ALP), calcium (Ca), creatinine (Cr), and glucose, will be measured by using automated techniques in the institute (Peking Union); 4. BMD measurements: Lumbar spine (LS) and femoral neck (FN) BMDs by dual-energy x-ray absorptiometry (DXA) (Lunar or Norland) at PK-VF sites. BMD calibration: The participant's BMD were evaluated by the same type of DXA as previous. The coefficients of variation of the seven hospitals were 0.75% to 1.7% for LS and 0.56% to 1.0% for FN. Cross-calibration equations between machines are: LS BMD (g/cm\^2) Lunar = 1.012 × Norland + 0.0137 and, FN BMD (g/cm\^2) Lunar = 1.0377 × Norland + 0.00026 5. Vertebral fracture diagnosis: Lateral radiographs of the thoracolumbar spine (T4-L5) were taken at PK-VF sites. Vertebral fractures will be assessed using Genant's semi-quantitative visual criteria. Two specialist radiologists will independently evaluate and diagnose vertebral fracture. A worsened existing vertebral fracture will be regarded as a new vertebral fracture. In 2007-2008 study(Published article about this study could be found in Pubmed, PMID: 24760246), 2070 participants were recruited in this cohort, and 837 subjects (40%) were diagnosed as osteoporosis. After 5 years, 1242 subjects agreed to be re-evaluated in 2013. Questionnaires and blood samples were collected, and BMD and spine x-ray were obtained at the 5-year follow up. We estimate that around 625 subjects would be diagnosed as osteoporosis. The remaining works include blood sample test (25(OH)D, CTX and P1NP),spine x-ray films reading, data input and statistical analysis, paper writing and publication.

Interventions

OTHERQuestionaire survey

We used a questionnaireto collect clinical data of the subjects. The questionnaire includes basic data, menstruation and pregnancy, habits and customs, daily activity, common healthy situation, history of drugs and history of factures.

RADIATIONBone mineral density examination

We use dual energy X-ray absorptiometry (DXA) to exam the BMD at lumbar spine (L2-4, LS) and hip.

X-ray of thoracic and lumbar spine was taken, and the pictures were read by radiological specialists. The diagnosis of vertebral fracture was executed according to Genant's semiquantitative technique.

OTHERBiochemical markers analysis

Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
50 Years to 108 Years
Healthy volunteers
Yes

Inclusion criteria

1. postmenopausal women (normally over 50 years old and years since menopause over than 1 year) in Peking. 2. participants without any fracture in 2007 PK-VF study were included in the prospective study investigating the association of bone turnover markers/BMD/25(OH)D with fracture incidence.

Exclusion criteria

participants with years since menopause less than 1 year.

Design outcomes

Primary

MeasureTime frameDescription
Non-vertebral Fracture Incidence5 yearNon-vertebral fractures were assessed by questionnaire survey.The overall incidence of non-vertebral fracture of the subjects is 7.18%( 70/975).
Vertebral Fracture Incidence5 yearVertebral fractures were assessed by lateral radiograph. The overall incidence of vertebral fracture of the subjects is 5.23%( 51/975)
Bone Mineral Density5 yearbone mineral density of Lumbar spine and femoral neck were measured by dual-energy X-ray absorptiometry (DXA) (Lunar or Norland)
Bone Turnover Markers and 25(OH)D5 yearC-terminal telopeptide of type I collagen (β-CTX), N-aminoterminal prepeptide of type I procollagen (P1NP), and 25-hydroxyvitamin D (25\[OH\]D) will be determined by a laboratory method of electrochemiluminescence (E170; Roche Diagnostics, Basel, Switzerland) in the institute (Peking Union)
Biochemical Markers5 yearFasting blood sample was collected for each subject. Common biochemical markers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP)were analyzed.
Serum Alkaline Phosphatase5 yearsFasting blood sample was collected for each subject. The level of serum alkaline phosphatase (ALP) was analyzed.
Serum Creatinine5 yearsFasting blood sample was collected for each subject.The level of serum creatinine(Cr) was analyzed.

Countries

China

Participant flow

Recruitment details

In 2007-2008, 2070 postmenopausal women participated in the previous PK-VF study. After 5 years, 1100 subjects agreed to be re-evaluated in 2013.

Pre-assignment details

All participants who agreed to be re-evaluated were enrolled in this study.

Participants by arm

ArmCount
Fracture Group
Fracture group included participants with new fractures during the 5 year follow-up visit. Fracture consists of non-vertebral fracture and vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
111
Non-fracture Group
Non-fracture group included participants without new fractures during the 5 year follow-up visit. Fracture consists of vertebral fracture and non-vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
864
Total975

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyPoor quality of radiological results125

Baseline characteristics

CharacteristicFracture GroupNon-fracture GroupTotal
Age, Continuous70.08 years66.09 years66.72 years
Body mass index25.21 kg/m^2
STANDARD_DEVIATION 5.04
25.47 kg/m^2
STANDARD_DEVIATION 4.85
25.46 kg/m^2
STANDARD_DEVIATION 4.82
Previous osteoporotic fracture
No previous osteoporotic fracture
39 participants576 participants615 participants
Previous osteoporotic fracture
Previous osteoporotic fracture
72 participants288 participants360 participants
Sex: Female, Male
Female
111 Participants864 Participants975 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants
Years since menopause21.36 years16.43 years16.92 years

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 975
serious
Total, serious adverse events
0 / 975

Outcome results

Primary

Biochemical Markers

Fasting blood sample was collected for each subject. Common biochemical markers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP)were analyzed.

Time frame: 5 year

ArmMeasureGroupValue (MEAN)Dispersion
Fracture GroupBiochemical MarkersSerum calcium2.302 mmol/LStandard Deviation 0.565
Fracture GroupBiochemical MarkersSerum phosphate1.148 mmol/LStandard Deviation 0.22
Fracture GroupBiochemical MarkersSerum glucose6.083 mmol/LStandard Deviation 1.81
Non-fracture GroupBiochemical MarkersSerum calcium2.263 mmol/LStandard Deviation 0.625
Non-fracture GroupBiochemical MarkersSerum phosphate1.122 mmol/LStandard Deviation 0.345
Non-fracture GroupBiochemical MarkersSerum glucose6.112 mmol/LStandard Deviation 1.281
Primary

Bone Mineral Density

bone mineral density of Lumbar spine and femoral neck were measured by dual-energy X-ray absorptiometry (DXA) (Lunar or Norland)

Time frame: 5 year

ArmMeasureGroupValue (MEDIAN)
Fracture GroupBone Mineral DensityLumbar spine BMD0.907 g/cm^2
Fracture GroupBone Mineral DensityFemoral neck BMD0.686 g/cm^2
Fracture GroupBone Mineral DensityTotal hip BMD0.788 g/cm^2
Non-fracture GroupBone Mineral DensityLumbar spine BMD0.956 g/cm^2
Non-fracture GroupBone Mineral DensityFemoral neck BMD0.732 g/cm^2
Non-fracture GroupBone Mineral DensityTotal hip BMD0.845 g/cm^2
Primary

Bone Turnover Markers and 25(OH)D

C-terminal telopeptide of type I collagen (β-CTX), N-aminoterminal prepeptide of type I procollagen (P1NP), and 25-hydroxyvitamin D (25\[OH\]D) will be determined by a laboratory method of electrochemiluminescence (E170; Roche Diagnostics, Basel, Switzerland) in the institute (Peking Union)

Time frame: 5 year

ArmMeasureGroupValue (MEDIAN)
Fracture GroupBone Turnover Markers and 25(OH)D25(OH)D13.21 ng/ml
Fracture GroupBone Turnover Markers and 25(OH)Dβ-CTX0.437 ng/ml
Fracture GroupBone Turnover Markers and 25(OH)DP1NP51.88 ng/ml
Non-fracture GroupBone Turnover Markers and 25(OH)Dβ-CTX0.401 ng/ml
Non-fracture GroupBone Turnover Markers and 25(OH)DP1NP51.57 ng/ml
Non-fracture GroupBone Turnover Markers and 25(OH)D25(OH)D12.49 ng/ml
Primary

Non-vertebral Fracture Incidence

Non-vertebral fractures were assessed by questionnaire survey.The overall incidence of non-vertebral fracture of the subjects is 7.18%( 70/975).

Time frame: 5 year

Population: In 1100 participants, 975 of them finished the questionnaire

ArmMeasureValue (NUMBER)
Fracture GroupNon-vertebral Fracture Incidence70 participants
Non-fracture GroupNon-vertebral Fracture Incidence0 participants
Primary

Serum Alkaline Phosphatase

Fasting blood sample was collected for each subject. The level of serum alkaline phosphatase (ALP) was analyzed.

Time frame: 5 years

ArmMeasureValue (MEAN)Dispersion
Fracture GroupSerum Alkaline Phosphatase79.4 U/LStandard Deviation 33
Non-fracture GroupSerum Alkaline Phosphatase77.5 U/LStandard Deviation 37
Primary

Serum Creatinine

Fasting blood sample was collected for each subject.The level of serum creatinine(Cr) was analyzed.

Time frame: 5 years

ArmMeasureValue (MEAN)Dispersion
Fracture GroupSerum Creatinine62.77 umol/lStandard Error 17.73
Non-fracture GroupSerum Creatinine64.91 umol/lStandard Error 14.59
Primary

Vertebral Fracture Incidence

Vertebral fractures were assessed by lateral radiograph. The overall incidence of vertebral fracture of the subjects is 5.23%( 51/975)

Time frame: 5 year

ArmMeasureValue (NUMBER)
Fracture GroupVertebral Fracture Incidence51 participants
Non-fracture GroupVertebral Fracture Incidence0 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026